FDA's cancer drug advisors will review 2 more dangling accelerated approvals for multiple myeloma, leukemia

In an attempt to get its house of accelerated approvals in order, the FDA is holding its second adcomm of 2021 to review cancer drugs that won accelerated approvals but failed to confirm clinical benefit in subsequent trials or have taken a long time to read those data out.